Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab versus placebo in biologic-naïve psoriatic arthritis (I1F-MC-RHBE)
2011-002328-42Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Ixekizumab with Placebo (2 arms). Primary endpoint: American College of Rheumatology 20 Index (ACR20) at Week 24. Started Nov 2014; status: completed.
02
Drugs
ixekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2011-002328-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002328-42.